Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A drug acting at metabotropic glutamate receptors has recently been reported to be an effective antipsychotic, breaking the rule that only dopamine receptor-blocking drugs have this property. The finding complements accumulating evidence that glutamatergic abnormalities are important in the pathophysiology of schizophrenia.

Original publication

DOI

10.1192/bjp.bp.107.045088

Type

Journal article

Journal

Br J Psychiatry

Publication Date

02/2008

Volume

192

Pages

86 - 87

Keywords

Antipsychotic Agents, Benzodiazepines, Humans, Receptors, Metabotropic Glutamate, Schizophrenia